>>MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Feb. 9, 2004--MDS Pharma Services, a leading provider of innovative drug discovery and development solutions and subsidiary of MDS, Inc. (NYSE:MDZ - News; TSX:MDS - News), and CardioDynamics (Nasdaq:CDIC - News), the innovator and leader of Impedance Cardiography (ICG) technology, today announced that the companies have formed a strategic alliance to offer CardioDynamics' BioZ ICG hemodynamic monitoring solution at MDS Pharma Services' Early Clinical Research centers worldwide.
"MDS Pharma Services is a leading provider of technologies and methods that allow early and rapid assessment of new drug compounds," said Jerry Merritt, Senior Vice President & General Manager, Early Clinical Research. "CardioDynamics' innovative ICG technology can provide our customers with noninvasive and cost-effective access to the important hemodynamic data they need to test and monitor the effects of new medications and treatment programs in Phase I and II clinical trials."
"With MDS Pharma Services' global presence and solid reputation, CardioDynamics has the opportunity to contribute to drug development and also increase its exposure to pharmaceutical leaders," stated Michael K. Perry, Chief Executive Officer of CardioDynamics. "Pfizer Global Research, Glaxo SmithKline, and Eli Lilly are already using our BioZ Systems for their research. The objective is for patients to have access to new medications and treatment programs as soon as possible. Both companies are committed to providing pharmaceutical partners with the tools and solutions they need to make this happen."
BioZ ICG's proprietary technology uses sensors on the neck and chest to quickly provide noninvasive access to vital cardiac parameters, including the amount of blood pumped by the heart each minute (cardiac output), and the force the heart has to pump against to deliver blood to the extremities (systemic vascular resistance). The BioZ's measurements provide researchers insight into the blood-flow and cardiovascular effects--both desirable and undesirable--of potential new medications under study. Prior to the BioZ, blood-flow monitoring in pharmaceutical clinical trials was typically limited to monitoring heart rate and blood pressure and did not provide a complete picture of a patient's status and response to a drug.
About MDS Pharma Services:
MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process -- early stage: lead optimization, pre-IND research and development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at www.mdsps.com. <<
snip
Cheers, Tuck |
